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ABSTRACT 
Ismail, Hamid Dafalla. IDENTIFICATION OF PAN-LIGANDS FOR PEROXISOME 
PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) USING COMPUTATIONAL 
VIRTUAL SCREENING WITH MOLECULAR DOCKING. (Major Professor: Dr. 
Mary A. Smith), North Carolina Agricultural and Technical State University. 
 
Peroxisome Proliferator-activated Receptors (PPARs) are ligand-activated nuclear 
receptors known for their major role in metabolic syndrome (MS).  Abdominal obesity, 
high blood pressure, increased glucose levels and low concentrations of high-density 
lipoprotein characterize MS.  Numerous studies proposed developing pan-agonists as 
potent drug candidates for the treatment and control of metabolic syndrome.  The 
objective of this study was to use virtual screening with molecular docking to identify 
potential pan-PPAR ligands from the ZINC database.  The 3D structural files of the 
receptor ligand binding domains (LBD), obtained from the Protein Data Bank (PDB), 
were energetically minimized and the binding pockets on each LBD were identified and 
measured.  The screening was performed by docking each compound from the lead-like 
database to the LBD of the three receptors using the AutoDock software.  The evaluation 
of the docking was based on the free energy of binding, position of the compound inside 
the binding pocket, and the protein residues that were involved in the binding.  Twenty-
seven out of approximately four million lead-like compounds were found to position 
themselves very well in the binding pockets of the three PPARs with minimal free energy 
of binding.  These pan-PPAR ligands may be strong candidates as pan-PPAR agonists 
that should be investigated further. 
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CHAPTER 1 
INTRODUCTION 
Peroxisome proliferator-activated receptors (PPARs) are a group of globular 
proteins that belong to the nuclear receptor super-family.  They are activated when they 
bind to ligands and play important roles as transcription factors and major regulators of 
the genes involved in lipid and carbohydrates metabolism, and storage of fatty acids [1].  
PPARs are divided into three isotypes; PPARα, PPARδ, and PPARγ, that differ in 
locations, ligand specificity, and functions [2].  PPARα is produced in the liver, heart, 
and muscle.  It can be activated endogenously by fatty acids to regulate the genes 
involved in the metabolism of lipids and lipoproteins in the liver and the oxidation of 
fatty acids in skeletal muscles.  Exogenously it can bind to a diverse set of ligands 
including prostaglandins, plasticizers, and synthetic fibrate drugs.  The PPARδ gene is 
expressed ubiquitously but most abundantly in brain, adipose tissue, skin, and kidney.  It 
is activated by both saturated and unsaturated fatty acids, and it has been found to have a 
role in the regulation of fatty acid oxidation and in modulating the level of the high 
density lipoprotein (HDL) [3].  PPARγ gene is expressed in three isoforms (γ1, γ2, and 
γ3) in many organs including heart, muscle, large intestine, pancreas, spleen, adipose 
tissue and macrophages [4].  Endogenously, PPARγ has a low affinity for naturally 
occurring fatty acids, eicosanoids, prostaglandins and their metabolites.  It exhibits a 
preference for essential polyunsaturated fatty acids.  Thus, it may act as a fatty acid 
sensor along with the target genes associated with lipid and glucose homeostasis [5].  
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PPARγ agonists have been found to increase the action of insulin and to lower the serum 
glucose in patients with type 2 diabetes mellitus [6].  
A recent study has shown that approximately 40 million individuals in the United 
States are afflicted with the metabolic syndrome (MS) and the prevalence increases with 
age in the western societies.  MS, is a cluster of disorders characterized by abdominal 
obesity, high blood pressure, increased fasting glucose levels and low concentrations of 
HDL which can lead to insulin insensitivity and type 2 diabetes [7]  Since PPARs 
mediates lipid and glucose metabolism, they have been intense pharmacological targets 
for the treatment and control of MS.  
There are a number of drugs that have been developed to treat the different 
disorders of MS by targeting specific PPAR isotypes.  Fibrates are synthetic ligands of 
PPARα that are used as lipid lowering drugs, while synthetic agonists of PPARγ, the 
TZDs, are used to increase insulin sensitivity in type 2 diabetic patients.  Independently, 
these drugs are ineffective as therapeutic treatments for the cluster of disorders that 
constitute the MS.  Therefore, researchers are searching for PPAR ligands with superior 
therapeutic and metabolic actions [8, 9].  Some researchers are trying to develop pan-
PPAR agonists, which are synthetic ligands that are capable of activating the three PPAR 
isotypes simultaneously.  Pan-PPAR agonists offer the potential to increase drug efficacy 
and reduce the risk factors associated with polypharmacy [10, 11].  The significant 
structural similarity of the ligand binding domain of the three isotypes makes it possible 
to find such alternative drugs.  Bezafibrate was the first drug to be identified and 
clinically investigated [12] followed by Indeglitazar, which was identified by coupling 
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low-affinity biochemical screening with high-throughput co-crystallography [10].  
Unfortunately, these pan-agonists did not pass phase 2 clinical trials.  Thus, 
investigations are pursuing different directions and adopting alternative approaches in 
search of more efficient pan-agonists.  
 The primary goal of this study was to apply computational techniques to identify 
potential pan-PPAR ligands among the millions of lead-like compounds stored in digital 
format in the data repository managed by ZINC, a free online database of commercially-
available compounds for ligand discovery.  To achieve the goal of this study, three key 
factors had to be investigated and determined: the size of the major cavity where ligand 
binding takes place; the residues that are the most frequently involved in binding; and the 
best positions for the ligands in the binding cavity in the three isotypes along with 
corresponding receptor-ligand conformations.  The significance of these three factors is 
obvious.  The major cavity was developed throughout the evolutionary path to host the 
ligand.  Studies have shown that the binding cavity is relatively large and formed by 
hydrophobic residues to force out any water molecules and to attract certain small 
amphipathic compounds [13].  Exploration of the cavities in the three isotypes was 
conducted by determining the cavities and voids on the proteins’ surfaces 
computationally using geometric triangulation.  The other two factors; the important 
residues in the contact and the positions of ligands and the corresponding conformations, 
were tested after conducting virtual screening with molecular docking.  The residues, 
which are critical for hydrogen bonding, were determined statistically by their probability 
distributions, based on the observed frequencies of involvement in ligand binding.  The 
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residues of high probability distributions were considered the most important in the 
contacts essential for ligand binding.  The positions were tested visually by observing the 
locations of the docked ligands and determining whether they are well-positioned in the 
binding pocket.  The quality of the positions of ligands and the complex conformations 
were evaluated by calculating the free energy of binding which is the measure of the 
binding fitness.  
Virtual screening exploits the large libraries of chemical structures to identify 
those structures which are most likely to bind to a target.  Moreover, it gives some 
information about the binding nature and whether it is good hit to be considered for 
further investigation.  
The study was mainly focused on identifying pan-PPAR ligands from lead-like 
compounds, which are classified as such based on their molecular weight, amenability for 
chemical optimization and other properties [14].  This study does not cover toxicity and 
other physicochemical properties of the identified ligands, which require laboratory 
investigations.  However, the identified ligands offer the opportunity for further research 
on drug discovery.   
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CHAPTER 2 
LITERATURE REVIEW 
2.1  Peroxisome Proliferator-Activated Receptors (PPARs) 
The peroxisome proliferator-activated receptors (PPARs) were given their name 
because the first discovered member of these receptors, the mouse PPARα, was shown to 
be activated by a diverse group of compounds that causes the proliferation of 
peroxisomes.  PPARs are members of the nuclear receptor (NR) superfamily that have 
evolved only in metazoan animals as transcriptional factors that mediate a variety of 
metabolic processes [15].  Three different isotypes of PPARs, known as PPARα, PPARγ, 
and PPARδ, have been identified.  They show distinct tissue distributions, physiological 
roles, and distinct but overlapping ligand specificity [16].  PPARs are ligand-activated 
transcription factors that function as gene regulators by binding to some small molecules 
such as hormones or dietary components [17].  They regulate both target gene expression 
and repression when they bind to a ligand [18].  The most conserved domains of this 
protein subfamily are the DNA binding domain (DBD) and the ligand binding domain 
(LBD) that, in addition to binding to ligands, is required for dimerization and interaction 
with transcriptional co-factors [19, 20].  They play important roles in lipid and glucose 
homeostasis, regulation of cellular differentiation, and tumorigenesis [21].  Although 
PPARs can form homodimers, they must heterodimerize with retinoid X receptor (RXR) 
to carry out most of their functions [22].  Despite their structural similarities, each 
member of the PPAR family is localized to certain parts of the body.  Location of 
receptors partially determines their function in the body and the different roles they can 
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play in medicine as drug targets.  PPARα is localized in liver, kidney, heart, and muscles 
and is important for the uptake and oxidation of fatty acids and lipoprotein metabolism 
[23].  Therefore, it is the target for the lipid lowering fibrates [24].  PPARγ is found in 
adipose tissue, large intestine, and macrophages [25].  It plays an important role in 
adipocyte differentiation as well as a receptor for the well-known class of anti-diabetic 
insulin sensitizer drugs, the thiazolidinediones (TZD) [26].  PPARδ is found in most cell 
types and it can bind to a number of agonists that play important roles in dyslipidemia, 
cancer treatment, and cell differentiation in the central nervous system [27].  
2.2  Structure of PPARs 
The structure of PPARs consists of five regions that differ in the degrees of 
homology.  These regions include, from N-terminal to C-terminal, the region (A/B), a 
DNA binding domain (C), a hinge region (domain D), and a ligand binding domain (E 
and F) (Figure 2.1).  
The A/B domain is highly variable among the members of the PPAR family.  It 
has a ligand-independent transcriptional activation function, which is referred to as AF-1.  
The AF-1 mediated gene activation often displays promoter-dependent and cell-type-
dependent specificities, indicating that this domain may be responsible for interactions 
with cell-specific co-regulatory proteins.  
The C- region is identified as the most conserved region.  It contains the DNA 
binding domain (DBD) which is composed of two zinc finger modules.  These two zinc 
modules are the characteristic feature of the DNA binding motif that distinguishes the 
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nuclear receptor from other DNA binding proteins.  Each zinc finger contains a group of 
four Cysteine (Cys) residues which co-ordinate a single zinc atom [28]. 
  
 
 
 
Figure 2.1. A typical nuclear receptor with its five characteristic domains 
       Domain D, the hinge region that connects domains C and E, is not well 
conserved and varies significantly in length among the nuclear receptors.  This domain 
participates in DNA rotation and co-repressor interaction.  
Domain E is the second most conserved region.  It includes the ligand-binding 
domain (LBD), which is made up of 13 α-helices and four short β-sheets.  The helices 
and the sheets are organized in three layers to form a hydrophobic pocket, where the 
ligand binds.  The PPAR structures obtained with X-ray crystallography show an 
exceptionally spacious ligand-binding pocket compared to other nuclear receptors, which 
explains the promiscuity of the PPAR ligand binding site.  
The C-terminal region is a multifunctional domain that mediates ligand binding, 
receptor dimerization, and transcriptional activation or repression [28].  
As shown by Uniprot database [29], the human PPARα consists of 468 amino 
acids (Figure 2.2) organized in 14 helices and 3 sheets (Tables 2.1 and 2.2).  The PPARα 
DBD is localized between the residues 99 and 173.  The DBD contains two zinc finger 
A/B C D E F 
Modulator DBD Hinge LBD 
AF-1 Zn++ fingers AF-2 
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motifs at the residual location 102 - 122 and 139 – 161.  The LBD extends over 189 
amino acids from residue 280 to residue 468. 
        10         20         30         40         50         60  
MVDTESPLCP LSPLEAGDLE SPLSEEFLQE MGNIQEISQS IGEDSSGSFG FTEYQYLGSC  
 
        70         80         90        100        110        120  
PGSDGSVITD TLSPASSPSS VTYPVVPGSV DESPSGALNI ECRICGDKAS GYHYGVHACE  
 
       130        140        150        160        170        180  
GCKGFFRRTI RLKLVYDKCD RSCKIQKKNR NKCQYCRFHK CLSVGMSHNA IRFGRMPRSE  
 
       190        200        210        220        230        240  
KAKLKAEILT CEHDIEDSET ADLKSLAKRI YEAYLKNFNM NKVKARVILS GKASNNPPFV  
 
       250        260        270        280        290        300  
IHDMETLCMA EKTLVAKLVA NGIQNKEAEV RIFHCCQCTS VETVTELTEF AKAIPGFANL  
 
       310        320        330        340        350        360  
DLNDQVTLLK YGVYEAIFAM LSSVMNKDGM LVAYGNGFIT REFLKSLRKP FCDIMEPKFD  
 
       370        380        390        400        410        420  
FAMKFNALEL DDSDISLFVA AIICCGDRPG LLNVGHIEKM QEGIVHVLRL HLQSNHPDDI  
 
       430        440        450        460        470  
FLFPKLLQKM ADLRQLVTEH AQLVQIIKKT ESDAALHPLL QEIYRDMY  
Figure 2.2. The sequence of human PPARα (Uniprot ID: Q07869) 
 
Table 2.1 
 PPARα regions 
Region Location Number Description 
DNA binding 99 – 173 75 Nuclear receptor 
Zinc finger 102 – 122 21 NR C4-type 
Zinc finger 139 – 161 23 NR C4-type 
Region 280 – 468 189 Ligand-binding 
Region 304 – 433 130 Required for heterodimerization with RXRA 
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Table 2.2 
PPARα secondary structures 
Secondary structure Location Number of residues 
Helix (H1) 201 – 217 17 
Helix (H2) 222 – 228 7 
Beta strand 239 – 241 3 
Helix (H3) 244 – 251 8 
Helix (H4) 268 – 292 25 
Helix (H5) 302 – 321 20 
Helix (H6) 322 – 324 3 
Beta strand 329 – 332 4 
Helix (H7) 333 – 335 3 
Beta strand 337 – 340 4 
Helix (H8) 341 – 346 6 
Helix (H9) 351 – 353 3 
Helix (H10) 356 – 366 11 
Helix (H11) 372 – 383 12 
Helix (H12) 394 – 415 22 
Helix (H13) 422 – 450 29 
Helix (H14) 458 – 467 10 
 
The human PPARδ is composed of 441 amino acids that form 14 helices, 3 
sheets, and a turn (Figure 2.3, Tables 2.3 and 2.4).  The PPARδ DBD extends between 
residue 71 and residue 145.  The zinc finger motifs are located at 74 – 94 and 111 – 133.  
The LBD extends over 189 residues between residue 280 and residue 468. 
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        10         20         30         40         50         60  
MEQPQEEAPE VREEEEKEEV AEAEGAPELN GGPQHALPSS SYTDLSRSSS PPSLLDQLQM  
 
        70         80         90        100        110        120  
GCDGASCGSL NMECRVCGDK ASGFHYGVHA CEGCKGFFRR TIRMKLEYEK CERSCKIQKK  
 
       130        140        150        160        170        180  
NRNKCQYCRF QKCLALGMSH NAIRFGRMPE AEKRKLVAGL TANEGSQYNP QVADLKAFSK  
 
       190        200        210        220        230        240  
HIYNAYLKNF NMTKKKARSI LTGKASHTAP FVIHDIETLW QAEKGLVWKQ LVNGLPPYKE  
 
       250        260        270        280        290        300  
ISVHVFYRCQ CTTVETVREL TEFAKSIPSF SSLFLNDQVT LLKYGVHEAI FAMLASIVNK  
 
       310        320        330        340        350        360  
DGLLVANGSG FVTREFLRSL RKPFSDIIEP KFEFAVKFNA LELDDSDLAL FIAAIILCGD  
 
       370        380        390        400        410        420  
RPGLMNVPRV EAIQDTILRA LEFHLQANHP DAQYLFPKLL QKMADLRQLV TEHAQMMQRI  
 
       430        440  
KKTETETSLH PLLQEIYKDM Y  
Figure 2.3. The sequence of human PPARδ (Uniprot ID: Q03181) 
 
Table 2.3 
PPARδ regions 
Region Location Number Description 
DNA binding 71 – 145 75 Nuclear receptor 
Zinc finger 74 – 94 21 NR C4-type 
Zinc finger 111 – 133 23 NR C4-type 
Region 254 – 441 188 Ligand-binding 
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Table 2.4 
 PPARδ secondary structures 
Secondary structure Location Number of residues 
Helix (H1) 170 – 173 4 
Helix (H2) 175 – 189 15 
Helix (H3) 194 – 200 7 
Beta strand 211 – 213 3 
Helix (H4) 216 – 223 8 
Turn  224 – 226 3 
Helix (H5) 241 – 264 24 
Turn  268 – 272 5 
Helix (H6) 275 – 294 20 
Helix (H7) 295 – 297 3 
Beta strand 302 – 305 4 
Helix (H8) 306 – 308 3 
Beta strand 310 – 313 4 
Helix (H9) 314 – 318 5 
Helix (H10) 322 – 339 18 
Helix (H11) 345 – 356 12 
Helix (H12) 367 – 388 22 
Helix (H13) 395 – 423 29 
Helix (H14) 431 – 437 7 
 
The Human PPARγ is the longest isotype as it consists of 505 amino acids 
forming 14 helices and 4 sheets (Figure 2.4, Tables 2.5 and 2.6).  The location of the 
DBD is between the residue 136 and residue 210 while the zinc finger motifs are located 
at 139 – 159 and 176 – 198. The PPARγ LBD consists of 189 residues from residue 
254 to residue 441. 
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        10         20         30         40         50         60  
MGETLGDSPI DPESDSFTDT LSANISQEMT MVDTEMPFWP TNFGISSVDL SVMEDHSHSF  
 
        70         80         90        100        110        120  
DIKPFTTVDF SSISTPHYED IPFTRTDPVV ADYKYDLKLQ EYQSAIKVEP ASPPYYSEKT  
 
       130        140        150        160        170        180  
QLYNKPHEEP SNSLMAIECR VCGDKASGFH YGVHACEGCK GFFRRTIRLK LIYDRCDLNC  
 
       190        200        210        220        230        240  
RIHKKSRNKC QYCRFQKCLA VGMSHNAIRF GRMPQAEKEK LLAEISSDID QLNPESADLR  
 
       250        260        270        280        290        300  
ALAKHLYDSY IKSFPLTKAK ARAILTGKTT DKSPFVIYDM NSLMMGEDKI KFKHITPLQE  
 
       310        320        330        340        350        360  
QSKEVAIRIF QGCQFRSVEA VQEITEYAKS IPGFVNLDLN DQVTLLKYGV HEIIYTMLAS  
 
       370        380        390        400        410        420  
LMNKDGVLIS EGQGFMTREF LKSLRKPFGD FMEPKFEFAV KFNALELDDS DLAIFIAVII  
 
       430        440        450        460        470        480  
LSGDRPGLLN VKPIEDIQDN LLQALELQLK LNHPESSQLF AKLLQKMTDL RQIVTEHVQL  
 
       490        500  
LQVIKKTETD MSLHPLLQEI YKDLY 
 
Figure 2.4. The sequence of human PPARγ (Uniprot ID: P37231) 
 
 
Table 2.5 
 PPARγ regions 
Region Location Number Description 
Chain 1 – 505 505 PPARγ 
DNA binding 136 – 210 75 Nuclear receptor 
Zinc finger 139 – 159 21 NR C4-type 
Zinc finger 176 – 198 23 NR C4-type 
Region 205 – 280 76 Interaction with FAM120B By similarity 
Region 317 – 505 189 Ligand-binding 
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Table 2.6 
 PPARγ secondary structures 
Secondary structure Location Number of residues 
Helix (H1) 236 – 253 18 
Helix (H2) 258 – 266 9 
Beta strand 275 – 277 3 
Helix (H3) 280 – 287 8 
Helix (H4) 289 – 292 4 
Beta strand 301 – 303 3 
Helix (H5) 305 – 329 25 
Helix (H6) 339 – 358 20 
Helix (H7) 359 – 361 3 
Beta strand 364 – 369 6 
Turn  370 – 373 4 
Beta strand 374 – 377 4 
Helix (H8) 378 – 383 6 
Helix (H9) 388 – 390 3 
Helix (H10) 393 – 403 11 
Helix (H11) 409 – 420 12 
Helix (H12) 431 – 452 22 
Helix (H13) 459 – 487 29 
Helix (H14) 495 – 501 7 
 
2.3 Ligand Binding Domain of PPARs 
The ligand effects on PPARs are mediated through the LBD, a region of 189 
amino acid residues at the C-terminal end of the receptor.  Besides ligand binding, the 
LBD also contains the transcriptional activation function 2 (AF-2), which consists of the 
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residues that play a key role in dimerization and trans-activation [28].  The structures of 
the three isotypes are very similar.  The LBD is composed of 13 α-helices and four 
strands of ß-sheet.  The ligand binding pocket is Y-shaped and it consists of a mouth 
opening and two arms.  The PPAR’s ligand binding pocket is about 1400Å3, which 
allows the PPARs to interact with a number of different ligands.  There are conserved 
polar resides, which are involved in a hydrogen bonding network that interacts with the 
ligands upon binding [30]. The conserved residues that form a hydrogen bonding network 
in one of the two arms assist in holding the AF2-helix in an active conformation to 
promote co-activator binding.  The second arm is highly hydrophobic and is thus ideal for 
binding the hydrophobic tail of fatty acids via van der Waals interactions (VDW).  It has 
been found that about 80% of the LBD residues are conserved across PPAR isotypes, 
while the remaining 20% of the residues create the ligand specificity of each isotype [31]. 
2.3.1  PPARα LBD.  The ligand binding site in PPARα is situated in a large 
cavity and guarded by helices H3, H5, H7, H11, and H12 (Figure 2.5).  The cavity spans 
the LBD between the AF2 helix and the 3-stranded β- sheet.  The cavity splits upward 
and downward at the level of the β-sheet, along an axis parallel to helix H3, forming 
upper and lower distal cavities.  The mouth opening to cavity is found between helix H3 
and the 3-stranded anti-parallel β-sheet.  PPARα does not bind to ligands with large 
carboxylate head groups because in place of TYR-314 , PPARγ has a smaller equivalent 
residue, HIS-351.  The loop is highly flexible and partly covers the opening to the ligand-
binding site.  The mouth opening is further guarded by TYR-334 which forms a hydrogen 
bond with GLU-282 [32]. 
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Figure 2.5. PPARα LBD in complex with a ligand 
2.3.2  PPARδ LBD.  The PPARδ LBD consists of 12 α-helices and a three-
stranded β-sheet (Figure 2.6).  The elements of the secondary structure create a large 
ligand-binding cavity of an approximate volume of 1300 A°
3
.  The significantly narrower 
cavity adjacent to the AF-2, helix 12, prevents PPARδ from binding to the large headed 
TZDs [33]. 
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Figure 2.6. PPARδ LBD in complex with a ligand 
2.3.3  PPARγ LBD.  PPARγ LBD is comprised of three layers made up of 13 
helices and a small four-stranded β-sheet (Figure 2.7).  It is very similar to that of 
PPARα, with the exception of an extra helix, called H2`, located between the first β-
strand and H3.  The two outer layers of the LBD are formed by the three long helices 
(H3, H7, and H10/H11).  The region between α-helix 1 and α-helix 3 contains an 
insertion of more than 20 amino acid residues forming two helices, 2a and 2b, separated 
by a β-strand. The middle layer is formed by helices (H4, H5, H8, and H9) and it 
occupies only the top half of the domain leaving very large cavity at the bottom half of 
the LBD (1400 Å
3
).  This LBD pocket is relatively large and has a three-arm Y shape, 
allowing ligands of multiple branches or a single branch to bind to the LBD in multiple 
conformations.  PPARγ binds to ligands with large carboxylate head groups because of 
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the smaller HIS-351 that allows the ligand to enter the binding pocket [34].  On the lower 
half of the LBD, the right-hand side is closed by a two-stranded β-sheet and, on the left-
hand side, by the short C-terminal α-helix (H12) of the receptor, which constitutes the 
receptor’s ligand-dependent AF-2 region.  Helix 12 covers the ligand-binding pocket and 
changes its conformation upon binding with ligands.  This helix forms hydrophobic 
interactions with the rest of the receptor, a weak hydrogen bond between HIS-351 and 
TYR-501, and a salt bridge between LYS-347 and ASP-503.  This salt bridge is critical 
for transcriptional activation and has a stabilizing effect on the active LBD [35]. 
 
Figure 2.7. PPARγ LBD in complex with a ligand 
2.3.4  AF-2 domain.  The AF-2 domain is essential for ligand binding to the 
PPAR LBD and the function of the receptor (Figure 2.8).  When a ligand binds to the 
LBD, helix H12 of AF-2 closes on the ligand-binding concavity, reducing conformational 
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flexibility of the LBD and forming a structure that is ideal for co-activator binding.  It has 
been determined that residues GLU-352, ARG-425, ARG-471, and TYR-505 (in PPARγ) 
are involved in a hydrogen bonding network that stabilizes the AF-2 helix in an active 
conformation upon ligand binding [36, 28].  
 
Figure 2.8. PPARγ LBD with AF-2 domain and a ligand 
2.4  PPAR DNA Binding Domain 
The DBD (Figure 2.9) is located in the center of the receptor and is comprised of 
highly conserved residues, two zinc-binding sites and sequence specific residues that 
direct the binding of PPAR to a consensus DNA sequence AGGTCA.  This consensus 
sequence designates the peroxisome proliferator DNA response element (PPRE) [36, 28].  
It has been shown that the DNA PPRE conformation contributes to the binding of PPAR 
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to DNA via a head-to-tail interaction between the PPAR DBD and RXR DBD using 
residues GLN-206 and ARG-209 on RXRα and ASN-188 on PPARγ [37, 38].  
 
Figure 2.9. PPAR DBD binding to DNA 
2.5  PPAR Ligands 
PPARs are activated by the peroxisome proliferators (PPs), a group of chemicals 
such as the fibrate drugs, WY-14, 643, and plasticizers. In addition, PPARs are also 
activated by endogenous fatty acids and their metabolic products. PPs are similar in their 
chemical structures to endogenous and dietary fatty acids and their metabolites.  Both PPs 
and fatty acids contain carboxylic functional groups and a hydrophobic tails.  Many 
ligands of the PPARs have been identified; some of them are able to activate all three 
isotypes with varying efficacy and potency while others exhibit isotype specificity [39, 
40]. 
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A group of synthetic drugs such as troglitazone, pioglitazone, and rosiglitazone 
have been developed to treat and control metabolic diseases like diabetes.  These drugs 
function similarly to the endogenous ligands that bind to the PPARγ LBD to activate the 
receptor [41].  It has been found that rosiglitazone creates hydrogen interactions with its 
TZD group and HIS-351 and HIS-477.  The sulfur atom of the TZD occupies a 
hydrophobic pocket formed by PHE-391, GLN-314, PHE-310, LEU-358, ILE-354 and 
LEU-497, and the central benzene ring occupies a pocket formed by CYS-313 and MET-
392 [42].  PPARγ regulates the genes responsible for lipid metabolism and homeostasis 
and fatty acid transport as well as the genes that function in insulin signaling and glucose 
transport [43].  PPARα has been found to play a significant role in the regulation of 
uptake and oxidation of fatty acids [44].  Therefore, PPARα became an important target 
for atherosclerosis drugs because it reduces LDL cholesterol and increases HDL 
cholesterol.  The fibrates, which are a group of carboxylic acids, can bind to PPARα as 
agonists.  So, they can be used as drugs to treat hypercholesterolemia and hyperlipidemia 
[45].  PPARδ is expressed all over the body and might play a role in a number of diseases 
and disorders including cancer.  Synthetic PPARδ agonists are used in the treatment of 
some diseases of central nervous system [46].  
Pan-PPAR agonists are a class of compounds that are capable of activating the 
three PPAR isotypes simultaneously.  Recent studies suggest that pan-agonists offer the 
potential to improve the treatment of metabolic syndrome, a group of clinical conditions 
that include hypertension, obesity and type 2 diabetes mellitus.  Bezafibrate is a clinically 
tested pan-PPAR ligand that acts as a lipid-lowering drug.  It has been shown to increase 
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high density lipoprotein, lower triglycerides, enhance insulin sensitivity, and reduce 
blood glucose level.  Therefore, bezafibrate significantly reduces the risks of 
cardiovascular conditions and metabolic syndrome but also it has been reported that it has 
a number of side effects including muscle problems [47].  
The tables 2.7 - 2.12 [48] contain the best known endogenous and exogenous 
ligands for the three PPAR isotypes.  These ligands differ in their binding affinities and 
they range from very strong ligands to weak or partial ligands. 
Table 2.7 
PPARα exogenous ligands 
Ligand description 
 Fibrate and nonfibrate hypolipidemic drugs 
(bezafibrate, clofibrate, ciprofibrate, 
fenofibrate, gemfibrozil, nafenopin, 
Wy-14643) 
 Phytanic acid 
 Indomethacin 
 Dehydroepiandrosterone (DHEA) 
 Phthalates (DEHP, MEHP) 
 MK-886a 
 Valproic acid (VPA) 
 Telmisartan 
 Phytol 
 Pefluorinated fatty acids (PFOA, PFDA), 
perfluorosulfonic acid (PFOS) 
 Phenobarbital (PB) 
 Oxirane compounds 
 ETYA 
 Epoxyisoprostane 
 DRF-2519 
 Bm 17.0744 
 Benz[a]anthracene 
Di- and trichloroacetic acid (DCA, TCA) 
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Table 2.8 
PPARα Endogenous ligands  
Ligand description 
 LPL-treated VLDL  
 VLDL  
 5,6-epoxyeicosatrienoic acids (EET); 8,9-EET; 11,12-EET; 14,14-EET; 
20-hydroperxyeicosatetraenoic acid (20-HETE), 
20,14,15-hydroxyepoxyeicosatrienoic acids (20,14,15-HEET) 
 2-arachidonylglycerol (2-AG); 15-S-hydroxyeicosatetraenoic-glycerol ester  
(15-S-HETE-G) 
 Long-chain alkylamines  
 Saturated and unsaturated fatty acids  
 PGD2, PGD1  
 Leukotriene B4 (LTB4) 
 
Table 2.9 
PPARδ exogenous ligands 
Ligand description 
 Tetradecylthioacetic (TTA) 
 Wy-14643 
 VPA 
 Bezafibrate 
 Sulindac sulfidea 
 Benz[a]anthracene 
 Treprostinil sodium 
 GW-501516 
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Table 2.10 
PPARδ endogenous ligands 
Ligand description 
 LPL-treated VLDL  
 VLDL  
 Mono- and polyunsaturated fatty acids from triglycerides  
 Saturated and unsaturated fatty acids  
 Prostaglandin A1 (PGA1), PGD2, PGD1  
 oxVLDL, 13-S-hydroxyoctadecadienoic acid (13-S-HODE), 4-hydroxynonenol 
(4-HNE) 
 
Table 2.11 
 PPARγ exogenous ligands 
Ligand description 
 Thiazolidinediones (ciglitazone, pioglitazone, 
rosiglitazone, troglitazone, N-(2-[4-[2,4-dioxo 
(1,3-thiazolidin-5-yl)methyl]phenoxy]ethyl)-5- 
(1,2-dithiolan-3-yl)-N-methylpentanamide) 
 GW9662a 
 Indomethacin 
 Phthalate esters (MEHP, DEHP) 
 Bisphenol A diglycidyl ether (BADGE)a 
 Wy-14643 
 Glimepiride 
 Diclofenac 
 Anandamide 
 Sulindac 
 JTP-426467 
 Pemoline 
 Phenylacetate 
 Nimesulide 
 Curcumin 
 2-bromopalmitate 
 Tolbutamide, chlorpropamide, gliclazide, 
Glibenclamide 
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Table 2.12 
PPARγ endogenous ligands 
Ligand description 
 OxLDL, 9-S-hydroxyoctadecadienoic acid (9-S-HODE), 13-S-HODE  
 LPL-treated VLDL  
 15-S-HETE  
 Lysophosphatidic acid (LPA)  
 Hexadecylazelaicphosphatidylcholine (AzPC) 
 13-S-HODE, 15-S-HETE, 5-S-HETE, 12-S-HETE  
 Polyunsaturated acids including linoleic acid, linolenic acid, arachidonic acid, and 
eicosapentaenoic acid (EPA) 
 PGD1, PGD2, PGA1  
 Nitroalkene derivatives of linoleic acid (LNO2) 
 
2.6  Heterodimerization 
Once a PPAR is activated, it binds to DNA as a heterodimeric complex with 
retinoic X receptor (RXR).  The PPAR-RXR complex regulates the gene expression by 
interacting with the PPREs, which are located close to the target genes.  There are several 
genes that contain these PPRE motifs including acyl-CoA oxidase, peroxisomal 
bifunctional enzyme, liver fatty acid-binding protein, microsomal CYP4A, and others.  
Members of the RXR-interacting subgroup of NRs typically bind to DNA elements 
containing two copies of a direct repeat array spaced by 1–6 nucleotides (DR1–DR6). 
The consensus binding site (AGGTCA) is similar for all isotypes.  The interaction of 
PPAR and RXR directs the complex to bind to DR1 motifs.  However, if PPAR interacts 
with another transcription factor, this complex may no longer associate with DNA and 
the interacting protein may be removed from its normal site of action [49].  
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2.7  PPAR Cofactors and Corepressors 
Transcriptional coactivators and corepressors are a group of protein that interacts 
with nuclear receptors to repress or enhance their transcriptional activities [50].  In the 
absence of ligand, PPARs may bind to corepressors, which decrease the activity of the 
receptor [51].  Ligand binding induces a conformational change in the nuclear receptor 
that favors binding to coactivators.  The receptor-coactivator complex can then activate 
gene transcription by means of recruiting chromatin-modifying enzymes 
(acetyltransferases) or by forming a ‘bridge’ with the pre-initiation complex at the 
hormone-regulated promoter [52, 53].  The PPAR coactivators such as PCG-1 contain a 
nuclear receptor interaction domain (LXXLL) and possess enzymatic activity (histone 
acetyltransferase, HAT) [54]. 
2.8  The Mechanism of PPAR Transcriptional Regulation 
The PPAR responds to ligands in processes that lead to the expression of a 
number of target genes.  The ligand binding to PPAR initiates a signaling pathway that 
leads to dimerization of PPAR with retinoid X receptor (RXR).  The target genes are 
activated through direct binding of the PPAR-RXR heterodimer to the PPREs.  A PPRE 
region may be found as multiple copies close to the promoter region of a target gene [55].  
Once a ligand binds in the pocket of PPAR LBD, favorable interaction forces between 
the ligand and helix 12 firmly place helix 12 over the binding pocket, closing the pocket 
off from interaction with water molecules.  In this way, the helix 12 acts like a trap door, 
it closes once the ligand enters the binding pocket.  This conformational change leads to 
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the activation of PPAR targets by increasing the affinity of nuclear receptors for 
coactivators [56].  
2.9  Computational Ligand-Protein Docking 
Docking involves finding the most favorable binding modes of a ligand to the 
target of interest.  The binding mode of a ligand with respect to the receptor can be 
uniquely defined by its state variables.  These consist of its position, orientation, and 
conformation [57, 58].  Computational docking is used to predict the binding modes of 
two or more molecules.  It uses molecular dynamics force fields to calculate the free 
energy of binding of the ligand-protein complex and a search method such as genetic 
algorithm to identify all possible conformations.  Docking is defined as a multi-step 
process in which each step introduces one or more additional degrees of complexity.  The 
docking begins with the application of docking algorithms that position small molecules 
or probes in the active site.  Molecules may contain many conformations [58].  The 
sampling of these conformations can be performed to determine the identification of the 
best conformation.  Algorithms use scoring functions that are designed to predict the 
biological activity through the evaluation of interactions between compounds and 
potential targets [57].  The docking scoring function depends on estimation of 
electrostatic and van der Waals interactions.  The techniques used in molecular docking 
can be classified based on the three types of protein representations; atomic, surface, or 
grid.  AutoDock uses GRID to calculate interaction energy and to perform the docking 
process [57, 60].  
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Binding of a ligand (L) to a receptor (R) to form a ligand-receptor complex (LR) 
only takes place if the generated energy of interaction (∆Gbinding) overcomes the repulsive 
van der Waals forces.  Molecular interaction fields are used to investigate the energetic 
conditions that arise between molecules approaching each other.  The molecular fields 
describe the variation of interaction energy between a target molecule and a probe moved 
in 3D grid, which has been set around the target.  The probes reflect the chemical 
characteristics of a binding partner.  GRID, a program used by AutoDock, can calculate 
the molecular interaction fields from Cartesian coordinates.  The interaction energy is 
calculated on a grid of points surrounding the target molecule.  At each grid point the 
interaction energy between the probe and the target is calculated using the following 
empirical energy function [61]:  
∆Gbinding = Evdw + Eel + Ehb  ………………….. (1) 
where ∆Gbinding is the total interaction energy, Evdw is the van der Waals interaction 
energy, Eel is the electrostatic energy, and Ehb is the interaction energy due to hydrogen 
bond formation.  
The repulsive force of the van der Waals energy can be calculated by an empirical 
energy function.  For non-polar molecules the balance between the attractive forces and 
the short-range repulsive forces of van der Waals energy can be estimated with the 
Lennard-Jones potential [62].  
           
   
   
 
  
  
   
   
 
 
     
 
    ………(2) 
where  ɛ  is the well depth, σ is the collision diameter of the respective atoms i and j, and 
r is the distance between two atoms. 
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The electrostatic term of the energy function is calculated by Coulomb 
equation[62].  
           
    
       
  
   
  
    ……….….. (3) 
where N is the number of atoms in molecules A and B, respectively, and q the charge on 
each atom, ɛ0 is the permittivity of free space, which is an experimentally determined 
quantity with the approximate value 8.854 × 10
-12
 C
2
 N
-1
 m
-2
, and r is the distance 
between two atoms. 
A hydrogen bond is an interaction between a positively charged hydrogen atom 
and an electronegative acceptor atom.  The resulting distance between acceptor and donor 
atom is less than the sum of their van der Waals radii.  In contrast to other non-covalent 
forces, the hydrogen bonding interaction is directional as it depends on the orientation of 
the acceptor atom.  The GRID method uses an explicit energy term in experimental 
crystallographic data for hydrogen bonds.  The functional form of this term has been 
developed to fit experimental data [62]. 
In the grid, parameters for each type of atom in the molecule ar defined.  The 
parameters describe the strength of the non-bonded interactions namely; van der Waals, 
the electrostatic, and the hydrogen bond interactions [63]. 
The free energy of binding for the formation of a protein-ligand complex can also 
be expressed with the following equation [64]: 
ΔGbind = ΔH – T ΔS  ……………. (4) 
where ΔH represents the enthalpy, T represents the temperature in Kelvin, and ΔS 
represents the entropy.  Under equilibrium conditions 
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The free energy of binding can be expressed as follows:  
ΔG° = ΔH° - T ΔS° = - R T Log (Keq)  …. (5) 
where R is constant and Keq is the kinetic equilibrium constant. 
2.10  Drug-like Compounds and Lead-like Compounds 
In drug discovery, a number of properties have been outlined for orally 
deliverable drug-like molecules.  These properties include appropriate molecular weight, 
ionization constants, lipophilicity, polar surface area, and number of hydrogen donors or 
acceptors.  The drug-like molecule must be able to cross the cell membrane, while 
retaining the ability to be transported in plasma [65].  Lipinski formulated the so-called 
“rule of 5” as the general guidelines for boundary definition for orally administered drug-
like compounds.  These guidelines include the following criteria: 1) the molecular weight 
of the orally administered drug must not be more than 500; 2) the maximum number of 
hydrogen bond donors in the molecule must not exceed 5; 3) the maximum number of 
hydrogen bond acceptors in the molecule must not exceed 10; 4) the logarithm of 
partition coefficient between octanol and water (LogP) should not be more than 5; and 
finally 5) the above-mentioned four rules only apply to passive transport.  These criteria 
recognize that penetration through cell membranes is accomplished only rarely by 
molecules of high molecular weight, unless there is an active transport mechanism [66]. 
High throughput screening of the chemical compounds can lead to the discovery 
of lead compounds with higher MW, higher lipophilicity, and lowered solubility which  
can be optimized and enhanced as s clinical candidates [67].  Thus criteria for lead-
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likeness must include validated biological activity in screens, that is patentable, and have 
a good initial Drug Metabolism and PharmacoKinetics profile (DMPK).  Property ranges 
for lead-like compounds can be defined as: 1-5 rings, 2-15 rotatable bonds, MW less than 
400, up to 8 acceptors, up to 2 donors, and a logP range of 0.0 to 3.0.  The average 
differences in comparisons between drugs and leads include 2 less rotatable bonds, MW 
100 lower, and a reduction in logP of 0.5 to 1.0 log units.  Thus, one of the key objectives 
in the identification of lead-like compounds for screening is the need for smaller, less 
lipophilic compounds that, upon optimization, will yield compounds that still have drug-
like properties [68]. 
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CHAPTER 3 
MATERIALS AND METHODS 
3.1  PPAR LBD Structure Files 
Protein Data Bank files (PDB) for PPARs were obtained from Protein Data Bank 
repository.  The PDB files provide standard representation for macromolecular structure 
data derived from X-ray diffraction.  A PDB file representing the structure of the LBD 
was selected for each of the three PPAR isotypes.  The selected PDB files were 1I7G 
(PPARα) [69], 2XYW (PPARβ/δ) [70], and 2ZK0 (PPARγ) [71].  
3.2  Surface Topography of PPARs 
The ligand-binding on a receptor requires cavities on the receptor surface as well 
as specific amino acid positioning within it that create the physicochemical properties 
needed for a LBD to perform its function.  Therefore, exploring the cavities on the 
surfaces of the PPARs is important in the virtual screening to determine whether the 
docking of the ligands makes sense in terms of location and chemical bonding.  To 
explore the surface topography of the PPARs, CASTp (Computed Atlas of Surface 
Topography of proteins), was used to locate and measure pockets and voids on the PPAR 
LBDs.  CASTp is based on recent theoretical and algorithmic results of computational 
geometry to identify the cavities analytically [72, 73, 74].  CASTp is capable of 
identifying and measuring pocket and pocket mouth openings using a series of 
computational geometry methods, including Delaunay triangulation, alpha shape, discrete 
flow, and Voronoi diagram [74, 75].  The program starts the identification of the cavities 
by finding the polygon of the convex hull of the molecule that encloses all atoms.  The 
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polygon was triangulated by the Delaunay method.  Then the Voronoi diagram was 
formed from the Voronoi cells.  The alpha shape was formed by omitting the edges and 
vertices outside the molecule (Figure 3.1).  Once the alpha shape was formed, the area, 
volume, and cavities were measured. The cavities represent the empty triangles [75]. 
 
Figure 3.1. A Voronoi diagram and Delaunay triangulation of a molecule 
The PDB file for each PPAR LBD was examined with CASTp. The cavities of 
the LBDs were obtained and visualized with PyMol CASTp plug-in [76] as shown in 
Figure 3.2. 
 
Figure 3.2. PyMol with CASTp plug-in showing a cavity 
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3.3  Virtual Screening with Molecular Docking 
Virtual screening with molecular docking was used to search for pan-PPAR 
ligands from more than four million compounds.  Screening was performed through 
different processes that include  ligand library filtering, ligand preparation, PPAR 
preparations, grid parameter file (GPF) preparation, docking parameter file (PDF) 
preparation, and generation of python docking script that perform calculation of grid 
interaction fields and implementation of a search algorithm to search for the top hits with 
the minimal binding energy.  The entire process was performed under the linux platform 
to access the open source programs such as python and AutoDock.  The computational 
cost of the virtual screening conducted in this study was inexpensive and performed in 
two-week run-time using a multi-core personal computer of 4 GB random access memory 
(RAM).  
The virtual screening encompassed 4 separate procedures:  the PPAR preparation, 
compound preparation, docking, and docking results evaluation.  These four procedures 
were further split into different steps.  The flow chart in Figure 3.3 summarizes the 
different procedures and steps that were followed during the virtual screening processes 
in this study. 
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Figure 3.3 A flowchart of the key steps of the molecular docking protocol 
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3.3.1  Ligand libraries.  The compounds for screening were obtained from the 
ZINC database, a free database of commercially available compounds.  ZINC is provided 
by the Shoichet Laboratory in the Department of Pharmaceutical Chemistry at the 
University of California, San Francisco (UCSF) [79].  Subsets of more than four million 
lead-like compounds collected in libraries were downloaded in MOL2 format.  Those 
compounds were filtered based on a primary automated virtual screening so that only the 
compounds, the most likely to dock with PPARs, were chosen for the final docking with 
AutoDock.  The filtering was performed with iGEMDOCK, an award winning suite of 
automated screening tools developed by the Department of Biological Science and 
Technology & Institute of Bioinformatics National Chiao Tung University [81, 82, 83, 
84].  iGEMDOCK uses a simple empirical fitness scoring function to predict the 
compounds that are likely to dock to the target proteins:  
Fitness = van der Waals energy + H-bond energy + Electrostatic energy 
3.3.2  PPARs preparation.  A number of modifications were performed to the 
LBD PDB files.  These modifications included the addition of the missing hydrogen 
atoms, removing water molecules, and removing extra chains and alternate locations.  A 
python script was used to remove the unneeded records of the PDB file while the addition 
of the missing hydrogen atoms was performed with CHARMM (Chemistry at HARvard 
Molecular Mechanics), a widely-used program for macromolecular simulations 
(Appendix A).  Before docking, the PPAR molecules were minimized with CHARMM to 
identify a set of coordinates representing a stable molecular conformation and minimal 
potential energy.  The algorithm used to search for the global minimum energy was the 
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Steepest Descent (SD) and Adopted Basis Newton-Raphson (ABNR) methods (see 
Appendix A). After modifications and minimization, OpenBabel was used to convert the 
PDB files to PDBQT, a file format used by AutoDock.  
3.3.3  Ligand preparation.  OpenBabel was also used to convert the filtered 
lead-like compounds from MOL2 file to PDBQT file format.  The hydrogen atoms were 
added by AutoDockTools to the compounds which were missing the hydrogen atoms and 
the partial charge of each compound was calculated as well and added to the compound. 
3.3.4  Preparation of grid parameter files.  The grid parameter file contained 
the information about the parameters and methods for the grid computing.  The 
parameters were about grid-based potential energies files known as grid maps.  A grid 
map was calculated for each atom type existing in the compound to be docked.  A grid 
map consisted of a three dimensional lattice of regularly spaced points, surrounding the 
entire LBD (Figure 3.4).  Each point within the grid map was the sum of the pair-wise 
potential interaction energy of a probe atom of a particular type with each of the atoms in 
the LBD.  
 
Figure 3.4. AutoDockTools 
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3.3.5  Docking of the compounds.  Raccoon, developed by AutoDock, was used 
to automate docking.  The software needed the compound files, receptor files, grid 
parameter template file (GPF), and docking parameter script file (DPF) as inputs. All 
required input files created in the previous steps except for the docking script file, which 
was generated by Raccoon.  The docking script file contained the parameters needed to 
compute the pair-wise energy and the search method and search parameters needed to 
search for the global optimum.  Genetic algorithm (GA) was used as a search method.  
When the docking scrip file was run, the compounds were tested one by one 
against the three PPAR isotypes.  The output of the docking process was saved in the 
docking log files (DLG), which contains all docking results such as energies, hydrogen 
bonds, electrostatic and van der Waals interactions. Each compound tested for docking 
had a separate docking log file. The docking files were analyzed one by one to evaluate 
the docking results of the compounds. 
3.3.6  Evaluation of the docking results.  The docking log files of the identified 
pan-PPAR ligands were evaluated with AutoDockTools.  The DLG file for each ligand 
was opened with AutoDock and analyzed to identify the best conformations in terms of 
free energy of binding and docking position (Figure 3.5 and 3.6).  The chosen 
conformations of each ligand-PPAR complex were then built-up and saved as PDB files, 
which were visualized with PyMol. 
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Figure 3.5. Visualizing a ligand docked to a PPAR with AutoDockTools  
 
Figure 3.6. Binding energy histogram 
3.3.7  Docking control PPAR ligands.  The technique used in virtual screening 
was validated with four known PPAR ligands: unique alpha PPARα ligand, PPARδ 
ligand, PPARγ ligand, and pan PPAR ligand. These control ligands are known for their 
binding affinity and furthermore there are high resolution resolved 3D PPAR structures in 
complex with these ligands.  The control ligands were obtained as SDF file format from 
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Protein Data Bank and converted to AutoDock file format.  Then they were prepared, 
docked, and the results were analyzed with the same technique used for the compounds 
under investigation.  Finally the results of the docked control ligands were compared to 
the already known results, namely the resolved 3D structures, locations of the binding 
site, and residues involved in binding.  Table 3.1 shows the PDB files that were used in 
the comparison. 
Table 3.1 
The PPAR structures resolved by X-ray diffraction in complex with the control 
ligands 
PDB ID PPAR Ligand 
2P54 PPARα GW735  
2ZNP PPARδ TIPP-204 
3K8S PPARγ T2384 
3ET1, 3ET2, and 3ET3 PPARα, PPARδ, and 
PPARγ   
Indeglitazar 
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CHAPTER 4 
RESULTS AND DISCUSSION 
4.1  Selection of Compounds for Ligand Screening 
The ZINC database was selected as the source for the test compounds used in this 
study because it is the largest database of commercially-available lead-like compounds in 
ready-to-dock 3D format.  Only lead-like compounds were used for screening because of 
their potential to be used as drugs.  These compounds are capable of passing into the 
blood via the digestive track when they are used orally.  They meet the Lipinski’s rule of 
five for orally-administered drugs, the main criteria to be selected as a PPAR ligand 
candidate in this study.    
 4.2  Characterization of PPAR Cavities 
CASTp was used to identify the cavities and voids on each PPAR’s LBD.  The 
results showed that PPARs have pockets and voids of different shapes and sizes.  Some 
of these cavities have one or more mouth openings while others do not have any.  The 
finding confirmed that the binding site is located in the largest cavity.  We found that 
PPARγ has the cavity with the largest molecular surface area (1496.05 A2) followed by 
PPARα (1307.46 A2), and PPARδ (1274.94 A2) (Table 4.1).  The size of the cavity may 
determine the size of the ligand that binds to it.  The isotype with more spacious cavity 
might be able to bind to diverse sets of ligands varying in size and chemical nature.  The 
relatively small size of PPARδ may explain why there are less known common ligands 
between this isotype and the others.  On the other hand, the relative close cavity area of 
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PPARγ and PPARα indicates that dual ligands for these two isotypes are more likely to 
be found.  
Table 4.1 
The major pockets in the PPAR isotypes  
 Isotype 
Pocket Area (A
2
) 
# of mouths 
SA MS 
PPARα 648.009 1307.46 3 
PPARβ/δ 755.686 1274.94 3 
PPARγ 719.46 1496.05 2 
 
In addition to the major cavities, CASTp calculation predicted several smaller 
cavities and concavities in the ligand binding domains of the PPARS.  The cavities of 
each isotype along with their areas, volumes, and number of mouths, are listed in 
Appendix B.  PPARα and PPARδ have 37 cavities numbered from 1 to 37, while PPARγ 
has 35.  The major cavities found in PPARα, PPARδ, and PPARγ were 37, 37, and 35 
respectively.  The total areas of the largest cavities in each isotype (Table 4.2) indicate 
the space of their potential binding sites.  Our finding supports previous studies that 
showed that the PPARγ has a more spacious ligand binding site than the other two PPAR 
isotypes.  The spacious binding pocket suggests that the PPARγ binding site is more 
promiscuous and consequently more likely to accept diverse ligands in terms of size and 
chemical composition.  
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Table 4.2 
The total area and volume of the pockets of each PPAR isotype 
Isotype 
Pocket Area (A
2
) 
SA MS 
PPARα 1013.362 2955.85 
PPARδ 1182.285 3139.59 
PPARγ 1294.879 3547.23 
 
In visualizing the top cavities with PyMOL, we observed that the largest cavity on 
each isotype was located at the same binding site positions, reported by others in previous 
studies (Figure 4.1).  Based on this evidence we used the largest cavity to test our 
compounds for docking to the PPAR isotypes.   
     
 
Figure 4.1. The top seven cavities on PPAR LBDs 
Given the importance of the largest cavity in each PPAR isotype for ligand 
binding, we identified the residues that form these cavities.  Figures 4.2- 4.4 highlight the 
residues that form the binding cavities in the three isotypes, for  pocket 37 on PPARα and 
PPARδ and for pocket 35 on PPARγ.  The figures also show a similar sequence pattern, 
(A) PPARα (1I7G) (B) PPARδ (2XYW) (C) PPARγ (2ZK0) 
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shaded in green, across the three isotypes. Further investigation reveals that the amino 
acids forming the cavities are mostly hydrophobic. In addition, the first and last amino 
acids in the cavities of the three isotype are tyrosine residues.   This co-incidence might 
suggest a particular importance of tyrosine for ligand binding. 
199
- E T A D L K S L A K   R I Y E A Y L K N F   N M N K V K A R V I   L S G - - S N N P P   F V I U D M E T L C 
249
- M A E K T L - - - -   - - - - - Q N K E A   E V R I F U C C Q C   T S V E T V T E L T   E F A K A I P G F A 
299
- N L D L N D Q V T L   L K Y G V Y E A I F   A M L S S V M N K D   G M L V A Y G N G F   I T R E F L K S L R 
349
- K P F C D I M E P K   F D F A M K F N A L   E L D D S D I S L F   V A A I I C C G D R   P G L L N V G U I E 
399
- K M Q E G I V U V L   R L U L Q S N U P D   D I F L F P K L L Q   K M A D L R Q L V T   E U A Q L V Q I I K 
449
- K T E S D A A L U P   L L Q E I Y R D M Y                                  
 
Figure 4.2. The residues that form the largest cavity (pocket 37) on PPARα LBD 
 
174
- D L K A F S K U I Y   N A Y L K N F N M T   K K K A R S I L T G   K - - - - A P F V I   U D I E T L W Q A E 
224
- K G L V W K Q L V N   G L P P Y K E I S V   U V F Y R C Q C T T   V E T V R E L T E F   A K S I P S F S S L 
274
- F L N D Q V T L L K   Y G V U E A I F A M   L A S I V N K D G L   L V A N G S G F V T   R E F L R S L R K P 
324
- F S D I I E P K F E   F A V K F N A L E L   D D S D L A L F I A   A I I L C G D R P G   L M N V P R V E A I 
374
- Q D T I L R A L E F   U L Q A N U P D A Q   Y L F P K L L Q K M   A D L R Q L V T E U   A Q M M Q R I K K T 
424
- E T E T S L U P L L   Q E I Y K D M                                     
 
Figure 4.3. The residues that form the largest cavity (pocket 37) on PPARδ LBD 
 
207
- E S A D L R A L A K   U L Y D S Y I K S F   P L T K A K A R A I   L T G K T T D K S P   F V I Y D M N S L M 
257
- M G E D K I K F K U   I T P L Q E Q S K E   V A I R I F Q G C Q   F R S V E A V Q E I   T E Y A K S I P G F 
307
- V N L D L N D Q V T   L L K Y G V U E I I   Y T M L A S L M N K   D G V L I S E G Q G   F M T R E F L K S L 
357
- R K P F G D F M E P   K F E F A V K F N A   L E L D D S D L A I   F I A V I I L S G D   R P G L L N V K P I 
407
- E D I Q D N L L Q A   L E L Q L K L N U P   E S S Q L F A K L L   Q K M T D L R Q I V   T E U V Q L L Q V I 
457
- K K T E T D M S L U   P L L Q E I Y K D L                                  
Figure 4.4. The residues that form the largest cavity (pocket 35) on PPARγ LBD 
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These findings are consistent with the need for hydrophobicity of some residues, 
which is essential to push out the solvent and furnish a suitable environment for ligand 
binding.  Since ligands are hydrophobic or amphipathic, hydrophobic forces play a key 
role in forcing the ligands inside the ligand binding cavity.  Variations in hydrophobic 
force contribution may account for the variation in the affinity for certain ligands across 
the different isotypes. 
4.3  Identification of Pan-Ligands by AutoDock 
Twenty seven out of approximately 4 million lead-like compounds met the 
criteria for consideration as pan-PPAR ligands.  They were selected based on their 
position in the binding cavity and the free energy of binding after docking.  The identified 
ligands were found to position themselves very well in the binding cavity with minimal 
free energy of binding.  A cutoff of -6.0 kcal/mol of free energy of binding was set as 
threshold.  It was shown that all ligands tended to bind to the binding cavity and position 
themselves behind Helix3.  The number of hydrogen bonds formed between the ligands 
and the receptor residues never exceeded 5, complying with the Lipinski’s rule of five for 
orally administered drugs.  These results suggest that these ligands are strong candidate 
as potential drugs. 
The Figures 4.5 – 4.7 show one of the identified pan-PPAR ligands binding to 
each PPAR isotype.  The first image from left shows a wire structure model that depicts 
the hydrogen bond between the ligand (ID # p0.1-0) and the residue SER-280 of PPARα 
LBD.  The image in the middle shows a surface protein structure model for the binding 
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pocket and the ligand inside. The image on the right is a ribbon model that shows the 
position of the ligand, which is close to Helix-3.  
     
Figure 4.5. Ligand p0.1-0 docked to the PPARα LBD 
 
     
Figure 4.6. Ligand p0.1-0 docked to PPARδ LBD 
 
    
Figure 4.7. Ligand p0.1-0 docked to PPARγ LBD 
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The complete list of the identified pan-PPAR ligands with their chemical 
structures and names can be found in Appendix C, while their docking information such 
as free energy of binding and the hydrogen bonds can be found in Appendix D. 
4.4  Identification of Important Residues for Hydrogen Bonding 
After docking, the PPAR residues that formed hydrogen bonds, and most likely to 
participate in receptor/ligand contacts were determined, in addition to the number of H-
bonds an isotype makes with each pan-ligand.  The identification of the important 
residues complemented the identification of the pan-ligands. Future studies of the pan-
ligands can use these residues to predict where contacts for binding may occur.  
Determining the number of H-bonds between the receptor and the test compounds was 
important for confirming that the pan-ligands passed the Lipinski’s rule of five.  
We found that each ligand forms a number of non-covalent H-bonds ranging 
between 2 to 3 with residues in the binding sites of each isotype.  However, the residues 
involved in binding differed from one isotype to another for the same ligand.  By 
evaluating the probability distribution of the residues involved in hydrogen bonding with 
the ligands across the identified ligand conformations, we noticed that some residues had 
a high probability of involvement in hydrogen bonding.  Tables 4.3- 4.5 show the 
residues that were engaged in the ligand-protein contact in the three isotypes along with 
their frequencies and relative frequencies.  These residues were weighted by their 
frequencies which indicate how many times a residue was found to be involved in a 
hydrogen bond.  The relative frequency, the frequency of a residue divided by the total 
frequencies; indicate the probability distribution for each residue.  These probability 
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distributions quantify the likelihood that these residues might be involved in hydrogen 
bonding with any other ligand that binds to these LBDs.  These residues can be qualified 
as Important Residues (IR) for their role in hydrogen bonding. In PPARα, TYR-334, 
ASN-219, ALA-333, THR-279, MET-220, and GLU-286 were found to be the most 
frequent hydrogen bond formers (Table 4.3).  Figure 4.8 shows the probability 
distributions of the most hydrogen bond forming residues in PPARα..  
Table 4.3  
The important residues of PPARα LBD and their probability distributions 
Residue Frequency Relative Frequency 
TYR334 47 0.30 
ASN219 25 0.16 
ALA333 22 0.14 
THR279 19 0.12 
MET220 13 0.08 
GLU286 6 0.04 
GLU282 5 0.03 
SER280 3 0.02 
SER323 3 0.02 
CYS275 2 0.01 
CYS278 2 0.01 
HSD440 2 0.01 
LEU331 2 0.01 
GLY335 1 0.01 
LYS364 1 0.01 
THR283 1 0.01 
TYR33 1 0.01 
Total 155 1.0 
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Figure 4.8. The important residues of PPARα LBD and their probabilities 
In PPARδ, the most frequent hydrogen bond forming residues are ASN-307, 
ALA-306, THR252, MET192, THR-256, LYS-229, and GLN-230 (Table 4.4).  Figure 
4.9 shows the probability distributions of the most frequent hydrogen bond forming 
residues in PPARδ. 
Table 4.4 
The important residues of PPARδ LBD and their probability distributions 
Residue Frequency Relative Frequency 
ASN307 32 0.26 
ALA306 19 0.15 
THR252 16 0.13 
MET192 13 0.10 
THR256 10 0.08 
LYS229 7 0.06 
GLN230 5 0.04 
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Table 4.4 (Cont). 
CYS249 4 0.03 
HSD287 3 0.02 
LEU304 3 0.02 
ARG248 2 0.02 
MET293 2 0.02 
THR253 2 0.02 
TYR437 2 0.02 
GLY308 1 0.01 
HSD413 1 0.01 
ILE290 1 0.01 
SER296 1 0.01 
Total1 124 1.0 
 
 
Figure 4.9. The important residues of PPARδ LBD and their probabilities  
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The most frequent hydrogen bond forming residues in PPARγ were SER-342, 
ILE-267, GLU-343, HIS-266, ARG-288, GLU-291, and LYS-244. Table 4.5 lists the 
frequencies and relative frequencies (probability distributions) for the hydrogen bond 
forming residues in PPARγ while Figure 4.10 shows a graphical view of the probability 
distributions. 
Table 4.5 
The important residues of PPARγ LBD and their probability distributions 
Residue Frequency Relative Frequency 
SER342 46 0.36 
ILE267 24 0.19 
GLU343 12 0.09 
HSD266 11 0.09 
ARG288 10 0.08 
GLU291 8 0.06 
LYS244 5 0.04 
CYS285 2 0.02 
GLN345 2 0.02 
GLU369 2 0.02 
LYS474 2 0.02 
HSD449 1 0.01 
SER245 1 0.01 
SER289 1 0.01 
Total 127 1.00 
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Figure 4.10. The important residues of PPARγ LBD and their probabilities  
The contacts for the LBDs of the three isotypes with the ligands are listed in 
Appendix D.  The LBD residues contributing to the contacts together with the atoms that 
play a role as electron donors or acceptors in the residue are shown.  The number of 
hydrogen bonds agree with Lipinski's Rule of Five, which states that the number of 
hydrogen bond should not be more than five.  A cutoff of 2.8 Å was set as a threshold to 
exclude any interaction above that distance. 
By studying the locations of these important residues, we noticed that these 
residues belong to the residual groups that form the main binding cavities in the three 
PPAR isotypes respectively (Figures 4.11).  Such findings strongly support the results of 
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computational prediction of the binding cavities as shown in the beginning of this 
chapter.  The involvement of these residues in hydrogen bonding suggests that the 
mutation of such residues may affect the affinity of the LBDs of the receptors to ligands. 
   
Figure 4.11. The important residues in (a) PPARα (b) PPARδ (c) PPARγ 
4.5  Chemical Structures of the Identified Pan-ligands 
Once the pan-ligands were identified and selected, the chemical structure and 
International Union of Pure and Applied Chemistry (IUPAC) names for each compound 
was resolved with Accelrys Draw.  SMILES strings for each ligand was obtained by 
OpenBabel.  The chemical structures and SMILES strings for the 27 pan-ligands are 
found in Appendix C. 
4.6  Validation of the Computational Techniques Using Control Ligands 
The known PPAR agonists listed in Table 4.2 were used as controls to validate 
the docking technique used in this study.  These controls were prepared and docked in the 
same way as the lead test compounds were done.  The control results were quite 
convincing in showing that the control ligands docked and positioned themselves in the 
pockets of their respective PPAR LBD and did not dock or docked very poorly to 
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unexpected PPAR targets, complying with the specificity rules imposed on the LBDs of 
the three isotypes.  
The control ligands did not dock exactly as in the structures resolved with X-ray 
diffraction but a small margin of error was expected.  Figures 4.12 and 4.13 compare the 
actual X-ray structures with the structures obtained with the molecular docking. Tables 
4.7 and 4.8 indicate the free energy of binding and hydrogen bonds for each 
conformation.   
We noticed that the ligands positioned themselves well on the binding site close 
enough to Helix3 so that some residues from this helix may be involved in the contacts 
with the ligands.  In general, the slight deviations that were observed do not necessarily 
invalidate the techniques used to identify the pan-ligands.  The results show enough 
degree of certainty to support the computational techniques used in this study.   
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PPARα LBD in complex with GW735 (a) resolved by X-ray diffraction (2P54) (b) 
obtained with molecular docking 
 
           
PPARδ LBD in complex with TIPP-204 (c) resolved by X-ray diffraction (2ZNP) (d) 
obtained with molecular docking 
 
           
PPARγ LBD in complex with T2384 (e) resolved by X-ray diffraction (3K8S) (f) 
obtained with molecular docking 
Figure 4.12. PPAR LBDs in complex with the control ligands 
(a) (b) 
(c) (d) 
(e) (f) 
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PPARα LBD in complex with Indeglitazar (a) resolved by X-ray diffraction (3ET1) (b) 
obtained with molecular docking 
 
           
PPARδ LBD in complex with Indeglitazar (c) resolved by X-ray diffraction (3ET2) (d) 
obtained with molecular docking 
 
           
PPARγ LBD in complex with Indeglitazar (e) resolved by X-ray diffraction (3ET3) (f) 
obtained with molecular docking 
Figure 4.13. PPAR LBDs in complex with the control pan-ligand 
(a) (b) 
(c) (d) 
(e) (f) 
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Table 4.6 
The residues of the three PPARs that form H-bond with the control ligands 
PPAR Control Ligand Binding Energy H-bonds 
PPARα GW735 -7.57 
-6.43 
GLN264:HN1 
GLN264:HN3 
PPARδ TIPP-204 -6.8 LYS229:HN 
PPARγ T2384 -7.37 
-6.44 
HSD266:HD1 
THR297:HG1 
LYS319:HZ3 
 
Table 4.7 
The residues of the three PPARs that form H-bond with the control pan-ligand 
PPAR Control Ligand Binding Energy H-bonds 
PPARα Indeglitazar -7.88 
 
-7.43 
 
 
-7.31 
 
 
-7.19 
-7.17 
-6.8 
GLN445:HE21 
LYS448:HZ1 
LYS204:HZ2 
LYS208:HZ2 
HSD411:HD1 
LYS204:HZ2 
LYS208:HZ2 
HSD411:HD1 
TYR334:HN 
GLN264:HN1 
CYS275:HG1 
PPARδ Indeglitazar -7.75 
 
 
 
-7.65 
 
-7.37 
 
 
-7.37 
ASP174:HN3 
LEU175:HN 
LYS176:HZ2 
SER179:HG1 
LYS229:HN 
THR252:HG1 
HSD389:HD1 
LYS398:HZ2 
LYS402:HZ1 
MET192:HN 
ASN307:HN 
PPARγ Indeglitazar -7.33 
-6.93 
-6.44 
HSD266:HD1 
ARG288:HE 
LYS230:HZ1 
THR238:HG1 
LYS240:HZ2 
 
 
 
57 
 
CHAPTER 5 
CONCLUSION 
In this study, twenty seven out of the four million lead-like compounds, stored in 
the ZINC database, were identified as PPAR pan-ligands based on results obtained by 
computational analysis techniques. As pan-ligands the compounds comply with 
Lipinski’s rule of five and dock very well in the binding cavity of the three isotypes with 
a minimal free energy of binding.  All the twenty seven successfully met these criteria 
when evaluated on the basis of their docking position in the binding sites, free energy of 
binding, and the number of hydrogen bonds they form.  In addition to meeting the 
criteria, these pan-ligands were found to be chemically similar to known PPAR’s ligands 
that have been used as drugs. They have the hydrophobic carboxylic and hydrophilic 
properties required for them to pass through the gates of the binding cavities of the three 
isotypes and form hydrogen bonds with the polar residues within the binding sites. The 
entrance of the ligands into the cavities to be in contact with the binding site is the most 
critical part of the PPAR activation process that mediates the allosteric change in the 
AF2-helix that leads to the interaction of the receptors with the DNA to regulate the 
target genes.  Thus, the identified pan-ligands are strong potential pan-PPAR agonists.  
To validate the computational techniques used in this study, known PPAR ligands 
were tested against the three isotypes as positive and negative controls. The control 
ligands behaved similarly and met the study criteria, asserting that the computational 
techniques were capable of discriminating for the pan-PPAR ligands.  
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We found that the computational virtual screening with molecular docking was 
efficient, fast, straightforward and economical, but confirmation of the ligands as pan-
agonists will require laboratory investigation. Each ligand represents the potential for 
discovering a potent pan-PPAR agonist in the laboratory.  Drug optimization may be 
needed to ensure that these compounds can activate the PPARs simultaneously to control 
multiple genes involved in the metabolic syndrome with minimal side effects. 
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APPENDIX A 
CHARMM SCRIPTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHARMM scripts: The first one adds H-atoms to the PDB file. The second one 
minimizes the structure.  
! protein topology and parameter 
open read card unit 10 name toppar/top_all22_prot.rtf 
read rtf card unit 10 
open read card unit 20 name toppar/par_all22_prot.prm 
read para card unit 20 flex 
! Read pdb file and extract chain A and give it a name (PROA) 
open read card unit 10 name 1i7g.pdb 
read sequence pdb unit 10 
generate PROA setup warn first NTER last CTER 
open read card unit 10 name 1i7g.pdb 
read coor pdb  unit 10 resid 
!Add h-atoms 
ic param 
ic build 
prnlev 0 
hbuild 
prnlev 5 
ENERGY 
open write card unit 10 name li7g_PPARA.pdb 
write coor pdb  unit 10  
open write card unit 10 name li7g_PPARA.crd 
write coor unit 10 card 
open write unit 10 card name li7g_PPARA.psf 
write psf  unit 10 card 
stop 
 
 
! protein topology and parameter 
open read card unit 10 name toppar/top_all22_prot.rtf 
read  rtf card unit 10 
open read card unit 20 name toppar/par_all22_prot.prm 
read para card unit 20 flex 
! Read PSF and Coordinates 
open read unit 10 card name li7g_PPARA.psf 
read psf  unit 10 card 
open read unit 10 card name li7g_PPARA.crd 
read coor unit 10 card 
mini SD   nstep 1000 nprint 100 
mini ABNR nstep 1000 nprint 100 
open write unit 10 card name li7g_PPARA_min.pdb 
write coor unit 10 pdb   
open write unit 10 card name li7g_PPARA_min.crd 
write coor unit 10 card 
close unit 10 
stop 
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APPENDIX B 
PPAR CAVITIES 
Cavities and voids of PPARα LBD 
ID No. of mouth 
Cavity Area 
Solvent Accessible Molecular  
8 1 0.106 17.58 
9 1 1.392 16.79 
10 0 0.456 34.04 
11 1 4.785 23.99 
12 0 0.002 25.20 
13 1 1.668 23.68 
14 1 5.680 20.4 
15 0 0.281 31.87 
16 1 3.895 27.61 
17 0 0.875 37.59 
18 1 2.216 34.68 
19 1 4.276 40.33 
20 1 1.086 5.62 
21 1 1.627 33.25 
22 2 8.325 45.79 
23 1 26.759 36.87 
24 1 6.783 104.99 
25 2 29.290 70.05 
26 1 12.071 36.78 
27 1 9.662 68.14 
28 1 11.486 71.24 
29 0 15.545 119.53 
30 1 20.759 64.72 
31 1 28.657 64.05 
32 0 13.144 79.02 
33 3 25.118 119.84 
34 1 29.032 71.09 
35 1 38.292 79.57 
36 1 61.626 110.56 
37 3 648.009 1307.46 
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Cavities and voids of PPARδ LBD 
ID No. of mouths 
Cavity Area 
Solvent Accessible Molecular  
3 1 0.206 19.43 
4 0 0.027 27.40 
5 1 0.428 21.30 
6 1 0.297 19.10 
7 0 0.507 42.44 
8 0 1.178 41.85 
9 0 1.208 54.39 
10 1 3.034 24.38 
11 0 1.181 42.33 
12 0 1.023 39.30 
13 0 2.191 50.08 
14 0 0.838 44.27 
15 1 2.964 27.27 
16 1 5.242 32.08 
17 2 4.883 21.07 
18 0 3.073 74.17 
19 0 3.400 52.64 
20 1 6.831 50.39 
21 1 10.322 49.47 
22 0 1.071 40.01 
23 1 20.477 42.13 
24 1 11.038 37.63 
25 0 3.664 58.63 
26 1 12.523 54.69 
27 1 21.350 45.26 
28 1 25.586 54.72 
29 1 26.945 73.11 
30 0 8.546 87.22 
31 1 19.265 82.95 
32 1 34.013 68.65 
33 1 24.598 79.65 
34 1 49.931 83.28 
35 1 30.088 65.15 
36 2 88.528 214.26 
37 3 755.686 1274.94 
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Cavities and voids of PPARγ LBD 
ID No. of mouths 
Cavity Area 
Solvent Accessible Molecular  
3 1 1.515 1.82 
4 1 2.014 2.09 
5 0 0.014 27.44 
6 0 0.021 26.53 
7 0 0.179 31.09 
8 1 2.348 11.87 
9 1 0.149 16.64 
10 1 3.279 38.74 
11 1 2.839 27.68 
12 1 6.005 21.48 
13 1 1.702 28.63 
14 0 3.107 61.78 
15 1 12.729 39.90 
16 0 5.702 61.54 
17 1 18.197 53.57 
18 1 6.637 42.32 
19 0 3.920 55.26 
20 0 4.681 59.45 
21 1 9.083 50.56 
22 1 20.961 45.16 
23 1 15.702 67.32 
24 1 17.030 49.34 
25 1 25.948 70.15 
26 1 14.059 55.63 
27 1 21.181 82.00 
28 0 17.818 109.30 
29 0 35.510 149.18 
30 1 52.065 101.12 
31 2 51.016 143.22 
32 2 68.229 144.00 
33 1 73.232 196.95 
34 1 78.542 153.67 
35 2 719.460 1496.05 
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APPENDIX C 
THE IDENTIFIED PAN-PPAR LIGANDS 
  
(1S,2S)-2-[(2-amino-6-isopropoxy-pyrimidin-4-
yl)amino]cyclohexanol 
N-(3,4-difluorophenyl)-2-(2-pyrazin-2-ylthiazol-
4-yl)acetamide 
c1(cc(nc(n1)N)N[C@@H]1[C@H](CCCC1)O)OC(C)
C 
C(C(=O)Nc1ccc(c(c1)F)F)c1nc(sc1)c1nccnc1 
p0.1-0  p0.2-0 
 
 
 
 
  
1-[3-(methoxymethyl)phenyl]-3-(1-methyl-4-
piperidyl)urea 
(5R)-5-(4-butoxyphenyl)-5-methyl-
imidazolidine-2,4-dione 
N(C(=O)Nc1cc(ccc1)COC)C1CCN(C)CC1 c1(ccc(cc1)[C@]1(NC(=O)NC1=O)C)OCCCC 
p0.3-1 p0.4-0 
 
 
 
 
 
 
7-[(2S)-2-(2,3-dihydro-1H-benzimidazol-2-
yl)pyrrolidin-1-yl]-2-methyl-oxazolo[5,4-d]pyrimidine 
(4-cyclopropyl-1,4-diazepan-1-yl)-[5-ethyl-1-(2-
pyridyl)pyrazol-4-yl]methanone 
N1(CCC[C@H]1[C@H]1Nc2c(N1)cccc2)c1c2nc(C)oc
2ncn1 
c1(c(cnn1c1ncccc1)C(=O)N1CCN(CCC1)C1CC
1)CC 
p0.5-1 p0.6-0 
 
 
 
 
 
 
73 
 
  
  
N-[(1S)-1-(2-furyl)ethyl]-2-(3-methyl-4-
methylene-quinazolin-2-yl)sulfanyl-
acetamide 
(3S)-3-cyclohexyl-N-[1-[2-(ethylamino)-2-oxo-
ethyl]pyrazol-3-yl]butanamide 
c1(nc2ccccc2c(=C)n1C)SCC(=O)N[C@@
H](C)c1occc1 
N(C(=O)C[C@H](C)C1CCCCC1)c1ccn(n1)CC(=O)NCC 
p0.7-1 p0.8-1 
  
 
 
N-(4-acetamidophenyl)-5,7-dimethyl-
[1,2,4]triazolo[1,5-a]pyrimidine-2-
carboxamide 
[(1S)-2-(3-fluorophenoxy)-1-methyl-ethyl] (2S)-1-(2-
methylpropanoyl)pyrrolidine-2-carboxylate 
C(=O)(Nc1ccc(cc1)NC(=O)C)c1nc2n(c(cc
(n2)C)C)n1 
O([C@@H](C)COc1cc(ccc1)F)C(=O)[C@H]1N(CCC1)C(=
O)C(C)C 
p0.9-1 p0.11-1 
 
 
 
  
N-(benzenesulfonyl)-2-hydroxy-benzamide 2-[(2R,6R)-2,6-dimethylmorpholin-4-yl]-N-(4-
phenylthiazol-2-yl)acetamide 
N(C(=O)c1c(cccc1)O)S(=O)(=O)c1ccccc1 C(=O)(Nc1scc(n1)c1ccccc1)CN1C[C@@H](C)O[C@@H](
C1)C 
p0.13-0 p0.14-0 
  
  
2-[4-(cyclopropanecarbonyl)piperazin-1-
yl]-N-(2-ethylphenyl)acetamide 
(1S,2R)-N-[(1R,2R)-2-(3-fluorophenyl)cyclopropyl]-2-(1-
methylpyrazol-4-yl)cyclopropanecarboxamide 
C(C(=O)Nc1c(cccc1)CC)N1CCN(CC1)C(
=O)C1CC1 
C(=O)(N[C@H]1[C@H](C1)c1cc(ccc1)F)[C@@H]1[C@@
H](C1)c1cn(C)nc1 
p0.15-0 p0.17-0 
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4-[[(2S)-2-
(cyclobutanecarbonylamino)propanoyl]amino]-N-
isobutyl-benzamide 
(2R)-N-cyclopentyl-2-(3H-imidazo[4,5-
b]pyridin-2-ylsulfanyl)butanamide 
c1(ccc(cc1)C(=O)NCC(C)C)NC(=O)[C@H](C)NC(=O
)C1CCC1 
[C@@H](CC)(C(=O)NC1CCCC1)Sc1[nH]c2c(
n1)cccn2 
p0.18-0  p0.22-0  
 
 
 
 
 
 
 
3-acetamido-N-[(1S)-1-(dimethylaminomethyl)-3-
methyl-butyl]-4-fluoro-benzamide 
dimethyl 9,10-dioxoanthracene-2,3-
dicarboxylate 
N(C(=O)c1cc(c(cc1)F)NC(=O)C)[C@@H](CC(C)C)C
N(C)C 
c1(cc2c(cc1C(=O)OC)C(=O)c1ccccc1C2=O)C(
=O)OC 
p0.23-0  p0.24-1 
 
 
 
 
 
 
 
(2S)-2-[(3-fluoro-4-methoxy-
phenyl)methylcarbamoylamino]-N-[(1R)-1-
methylpropyl]propanamide 
N-(1-isopropylpyrazol-4-yl)-4-pyrrol-1-yl-
benzamide 
N(C(=O)NCc1cc(c(cc1)OC)F)[C@@H](C)C(=O)N[C
@H](C)CC 
c1(ccc(cc1)n1cccc1)C(=O)Nc1cn(nc1)C(C)C 
p0.25-0 p0.26-1 
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(2R,4R)-4-hydroxy-1-[2-[(4-
methoxyphenyl)methylamino]-2-oxo-ethyl]pyrrolidine-
2-carboxamide 
N-methyl-4-[(E)-3-(3-oxazol-5-ylanilino)-3-
oxo-prop-1-enyl]benzamide 
N(C(=O)CN1[C@H](C[C@H](C1)O)C(=O)N)Cc1ccc(
cc1)OC 
C(=O)(Nc1cc(ccc1)c1ocnc1)/C=C/c1ccc(cc1)C(
=O)NC 
p0.27-0 p0.29-0 
  
 
 
(2S)-2-[4-(hydroxymethyl)-1-piperidyl]-N-[(1S)-1-(2-
methoxyphenyl)ethyl]propanamide 
(4R)-N-(3-oxoisoindol-5-yl)-4-phenyl-azepane-
1-carboxamide 
N(C(=O)[C@H](C)N1CC[C@@H](CC1)CO)[C@@H]
(C)c1c(cccc1)OC 
[C@H]1(CCCN(CC1)C(=O)Nc1cc2c(cc1)C=N
C2=O)c1ccccc1 
p0.30-1 p0.31-1 
  
 
 
(2R)-N-[(S)-cyano(o-tolyl)methyl]-2-imidazol-1-yl-
propanamide 
N-(1H-imidazol-2-ylmethyl)-2-(3-
methylphenoxy)ethanamine 
[C@@H](C#N)(c1c(C)cccc1)NC(=O)[C@@H](C)n1c
ncc1 
C(Oc1cccc(C)c1)CNCc1[nH]ccn1 
p1.1-0 p1.2-1 
  
 
 
(2R)-6-oxo-N-[2-(3-pyridyloxy)phenyl]piperazine-2-
carboxamide 
 
c1ccc(c(c1)NC(=O)[C@@H]1NC(=O)CNC1)Oc1cnccc
1 
 
p1.3-1  
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APPENDIX D 
H-BOND FORMING PPAR RESIDUES 
Ligand 
ID# 
PPARα PPARγ PPARβ/δ 
Binging 
Energy 
H-bond Binging 
Energy 
H-bond Binging 
Energy 
H-bond 
p0.1-0 -7.74 
-6.68 
-6.65 
-6.59 
 
-6.45 
-6.33 
 
-6.26 
 
 
-6.09 
SER280:HG1 
TYR334:HN 
TYR334:HN 
THR279:HG1 
TYR334:HN 
TYR334:HN 
THR279:HG1 
ALA333:HN 
TYR334:HN 
ALA333:HN 
THR279:OG1 
TYR334:HN 
ALA333:HN 
GLU282:OE1 
-7.34 
 
-7.34 
-6.99 
-6.77 
-6.76 
-6.72 
-6.38 
 
 
-6.27 
ILE267:HN 
SER342:HN 
SER342:HN 
 
SER342:HN 
GLU343:HN 
SER342:HN 
LYS244:HN 
LYS244:HZ3 
GLN345:HE22 
LYS244:Hz3 
GLN345:HE22 
-7.94 
-7.73 
 
-7.31 
 
 
-7.13 
 
-6.98 
 
-6.35 
ARG248:HE 
THR253:OG1 
CYS249:HG1 
HSD287:HE2 
HSD413:HE2 
TYR437:OH 
THR252:HG1 
ALA306:HN 
MET192:HN 
ASN307:HN 
 
 
p0.2-1 -7.45 
 
-7.29 
 
-7.0 
 
 
-6.83 
 
-6.62 
ALA333:HN 
TYR334:HN 
MET220:O 
ASN219:HD22 
LEU331:O 
THR279:HG1 
TYR334:HN 
ALA333:HN 
TYR334:HN 
 
-7.38 
-7.37 
-6.9 
 
-6.79 
-6.71 
-6.7 
 
ILE267:HN 
SER342:HN 
GLU343:HN 
SER342:HN 
CYS285:HG1 
SER289:HG1 
-7.63 
-7.55 
-6.99 
 
-6.91 
-6.8 
-6.66 
-6.38 
-6.32 
 
CYS249:HG1 
MET192:HN 
THR252:HG1 
GLN230:HN 
 
 
 
LYS229:HN 
ALA306:HN 
p0.3-0 -7.06 
 
-7.03 
 
 
-7.0 
-6.86 
 
-6.59 
-6.24 
THR279:HG1 
TYR334:HN 
TYR334:HN 
ASN219:HD22 
THR279:OG1 
TYR334:HN 
ASN219:HD22 
TYR334:HN 
MET220:HN 
TYR334:HN 
ALA333:HN 
CYS278:HG1 
-7.55 
-7.52 
-7.38 
-7.37 
-7.34 
 
-7.22 
-7.13 
-7.06 
-6.63 
SER342:HN 
SER342:HN 
 
SER342:HN 
HSD266:HD1 
GLU291:OE1 
 
 
ARG288:HE 
SER342:HN 
-6.31  
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p0.4-1 -6.7 
-6.68 
 
-6.48 
-6.03 
ASN219:HD22 
ASN219:HD22 
TYR334:HN 
SER323:HG1 
ASN219:HD22 
 
-6.88 
-6.81 
 
-6.79 
 
-6.71 
 
-6.45 
 
-6.36 
-6.32 
 
-6.06 
HSD266:HD1 
ILE267:HN 
SER342:HN 
ILE267:HN 
SER342:HN 
ILE267:HN 
SER342:HN 
ILE267:HN 
ILE267:O 
ILE267:O 
ILE267:HN 
ILE267:O 
ILE267:HN 
-6.69 
-6.67 
 
 
-6.66 
-6.5 
-6.27 
 
-6.03 
GLY308:HN 
ALA306:HN 
ASN307:HN 
MET192:HN 
LYS229:HN 
 
MET192:O 
SER296:HG1 
THR252:HG1 
 
p0.5-0 -8.08 
-8.06 
-7.92 
-7.67 
 
-7.6 
TYR334:HN 
TYR334:HN 
TYR334:HN 
ALA333:HN 
TYR334:HN 
SER280:HG1 
-8.56 
-8.48 
-8.44 
-8.37 
-8.19 
-8.07 
-6.41 
SER342:HN 
GLU343:HN 
SER342:HN 
SER342:HN 
SER342:HN 
ILE267:O 
 
-8.26 
 
-8.24 
 
-8.19 
 
-7.84 
 
-7.34 
-7.32 
-7.32 
 
-6.75 
THR252:HG1 
ASN307:HN 
LEU304:O 
ASN307:HN 
THR252:HG1 
ASN307:HN 
LEU304:O 
ALA306:HN 
 
ASN307:HN 
ARG248:HE 
ASN307:HN 
 
p0.7-0 -7.11 
-6.93 
 
 
-8.65 
 
-7.94 
-7.79 
-7.67 
-6.19 
 
SER342:HN 
GLU343:HN 
 
ARG288:HE 
SER342:HN 
LYS244:HN 
SER245:O 
-8.49 
-7.96 
 
-7.68 
-7.18 
-7.16 
-6.88 
-6.17 
 
ALA306:HN 
ASN307:HN 
GLN230:HN 
 
ASN307:HN 
 
ALA306:HN 
p0.8-1 -7.83 
-7.29 
-7.03 
-6.76 
 
-6.6 
TYR334:HN 
 
ALA333:HN 
ASN219:HD22 
TYR334:HN 
 
-8.27 
 
-7.95 
 
-7.41 
-7.36 
-7.32 
-7.02 
ARG288:HE 
SER342:HN 
ARG288:HE 
SER342:HN 
SER342:HN 
 
 
ARG288:HE 
-8.03 
-7.31 
-7.18 
-7.04 
-6.94 
-6.05 
 
 
ASN307:HN 
 
THR256:HG1 
THR256:HG1 
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p0.9-0 -8.09 
 
-7.7 
-7.5 
 
 
-7.49 
-7.37 
GLU282:OE1 
TYR334:HN 
 
ASN219:HD22 
THR279:HG1 
ALA333:HN 
MET220:HN 
GLU282:OE1 
CYS278:HG1 
TYR334:HN 
-9.73 
 
 
 
-9.27 
-9.26 
 
-9.1 
 
-8.43 
-8.41 
-8.18 
-8.15 
ILE267:HN 
SER342:HN 
GLU343:HN 
GLU291:OE1 
GLU343:HN 
GLU343:HN 
GLU291:OE1 
GLU343:HN 
GLU291:OE1 
 
SER342:HN 
GLU291:OE1 
HSD266:HD1 
-8.01 
-7.48 
-7.19 
THR252:HG1 
 
 
p0.11-0 -6.83 
-6.75 
-6.25 
 
 
TYR334:HN 
ASN219:HD22 
-6.76 
-6.71 
-7.17 
 
 
SER342:HN 
GLU291:OE1 
HSD266:HD1 
-7.09 
 
-6.94 
 
 
-6.69 
-6.38 
-6.06 
ALA306:HN 
ASN307:HN 
ALA306:HN 
ASN307:HN 
LYS229:HN 
ASN307:HN 
THR256:HN 
 
p0.13-0 -7.59 
 
 
-7.45 
-7.37 
 
-7.33 
 
 
-7.19 
-7.02 
-6.98 
-6.94 
-6.91 
GLU286:OE2 
MET220:HN 
ASN219:HD22 
HSD440:HE2 
MET220:O 
MET220:HN 
GLU286:OE2 
MET220:HN 
ASN219:HD22 
 
ASN219:HD22 
ASN219:HD22 
 
GLU286:OE2 
-8.38 
 
-7.89 
-7.85 
 
-7.84 
-7.75 
-7.64 
-7.47 
 
-7.43 
-7.32 
HSD266:HD1 
ILE267:HN 
ILE267:HN 
ARG288:HE 
SER342:HN 
ILE267:HN 
SER342:HN 
ILE267:HN 
HSD266:HD1 
SER342:HN 
SER342:HN 
SER342:HN 
-8.45 
 
 
-7.9 
-7.84 
 
-7.8 
-7.77 
 
-7.72 
 
-7.6 
 
-7.42 
-7.14 
-6.89 
 
GLN230:HN 
ALA306:HN 
THR252:HG1 
HSD287:HE2 
LYS229:HN 
ASN307:HN 
LYS229:HN 
THR252:HG1 
ALA306:HN 
LYS229:HN 
THR252:HG1 
TYR437:OH 
HSD287:HE2 
 
ILE290:O 
ASN307:HN 
ALA306:HN 
p0.14-0 -8.0 
-7.98 
-7.86 
-7.77 
-7.66 
-7.41 
-6.28 
THR279:HG1 
 
 
 
 
TYR334:HN 
LYS364:HZ3 
-8.57 
-8.37 
-7.97 
-7.77 
-7.63 
-7.39 
-7.36 
-6.43 
SER342:HN 
ILE267:O 
HSD266:HD1 
HSD449:HE2 
SER342:O 
SER342:HN 
SER342:HN 
GLU369:OE1 
-7.96 
 
-7.86 
-7.64 
-7.23 
-7.11 
-6.8 
THR252:HG1 
ALA306:HN 
 
ALA306:HN 
CYS249:O 
ASN307:HN 
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p0.15-0 -7.6 
-6.92 
 
 
-6.53 
-6.17 
 
THR279:OG1 
ASN219:HD22 
TYR334:HN 
GLU286:OE2 
TYR334:HN 
-7.1 
-6.92 
-6.88 
 
GLU369:OE1 
 
-6.29  
p0.17-0 -7.28 
-7.03 
-6.6 
-6.23 
TYR334:HN 
 
TYR334:HN 
CYS275:HG1 
-6.77 
-6.77 
-6.58 
 
ARG288:HE 
 
-7.09 
-6.67 
-6.65 
-6.63 
-6.61 
-6.26 
-6.18 
MET192:HN 
ASN307:HN 
ALA306:HN 
ASN307:HN 
MET192:HN 
 
 
p0.18-1 -7.51 
 
-7.39 
 
-7.38 
THR279:OG1 
ALA333:HN 
THR279:OG1 
ASN219:HD22 
ALA333:HN 
-7.73 
-7.67 
-7.53 
-7.36 
-7.11 
HSD266:HD1 
 
 
ARG288:HE 
SER342:HN 
-7.82 
 
-7.26 
-7.23 
-6.49 
THR252:HG1 
ALA306:HN 
 
 
 
p0.22-0 -7.48 
 
-7.48 
 
 
-7.34 
 
-7.33 
 
-7.28 
 
-7.26 
-7.17 
 
-6.65 
-6.49 
MET220:HN 
TYR334:HN 
ALA333:HN 
TYR334:HN 
THR279:HG1 
ALA333:HN 
TYR334:HN 
ALA333:HN 
TYR334:HN 
ALA333:HN 
TYR334:HN 
 
MET220:O 
MET220:HN 
ALA333:HN 
 
-7.71 
-7.59 
-7.42 
-7.34 
-7.26 
-7.14 
-7.11 
-6.81 
-6.8 
 
 
SER342:HN 
CYS285 
 
ILE267:O 
HSD266:HD1 
 
HSD266:HD1 
-7.4 
-7.11 
 
-6.99 
-6.92 
-6.84 
-6.67 
CYS249:HG1 
MET192:HN 
ASN307:HN 
LYS229:HN 
ASN307:HN 
ASN307:HN 
THR256:HG1 
 
p0.23-0 POOR  -6.3  -5.77 THR252:HG1 
ALA306:HN 
p0.24-0 -8.12 
-7.95 
 
 
-7.61 
 
-7.1 
-6.82 
ASN219:HD22 
MET220:HN 
TYR334:HN 
GLU286:OE2 
ASN219:HD22 
TYR334:HN 
 
CYS275:HG1 
-8.44 
-7.68 
-7.5 
-7.44 
-7.29 
-7.28 
-6.59 
-6.35 
SER342:HN 
 
 
 
HSD266:HD1 
 
LYS244:HZ3 
 
-7.69 
-7.2 
-7.16 
 
 
 
ALA306:HN 
ASN307:HN 
MET192:HN 
ASN307:HN 
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p0.25-1 -7.48 
 
-6.73 
-6.6 
 
 
 
-6.47 
-6.27 
 
ASN219:HD22 
MET220:HN 
 
TYR334:HN 
ALA333:HN 
THR279:OG1 
ASN219:HD22 
THR283:HG1 
THR279:OG1 
ALA333:HN 
-6.83 
-6.81 
-6.45 
 
-6.15 
SER342:HN 
SER342:HN 
ILE267:O 
SER342:HN 
 
-6.67 
-6.63 
-6.62 
-6.51 
-6.33 
-6.2 
-6.05 
ASN307:HN 
ASN307:HN 
 
THR253:HG1 
 
THR256:HG1 
THR252:HG1 
 
p0.26-1 -7.13 
 
-7.1 
 
-7.09 
-6.88 
-6.82 
-6.64 
ASN219:HD22 
TYR334:HN 
ASN219:HD22 
TYR334:HN 
TYR33:HN 
 
 
 
-7.05 
-07.02 
-7.01 
-6.96 
-6.95 
 
 
 
 
 
-7.49 
-7.46 
-7.41 
-7.32 
-7.3 
-7.1 
-7.07 
-6.77 
THR252:HG1 
THR252:HG1 
THR252:HG1 
 
 
THR256:HG1 
 
 
 
p0.27-0 -6.61 
-6.49 
 
 
-6.46 
-6.44 
 
 
-6.35 
 
 
 
-6.21 
THR279:HG1 
THR279:OG1 
TYR334:HN 
ALA333:HN 
ALA333:HN 
THR279:OG1 
TYR334:HN 
ALA333:HN 
TYR334:HN 
ASN219:HD22 
GLU286:OE1 
GLU282:O 
LEU331:O 
HSD440:HE2 
-7.13 
-7.02 
-6.39 
-6.33 
-6.28 
LYS367:HZ3 
ILE267:HN 
 
 
 
-6.28 
 
-6.08 
MET192:HN 
ALA306:HN 
MET192:HN 
p0.29-0 -9.16 
-8.97 
-7.87 
-7.82 
-7.78 
SER280:HG1 
SER323:HG1 
SER323:HG1 
 
 
HSD26
6:HD1 
ARG2
88:HE 
 -8.28 
 
-8.22 
-8.15 
 
-7.89 
-7.68 
-7.67 
-7.33 
MET192:O 
MET293:O 
 
MET192:O 
MET293:O 
ASN307:HN 
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p0.31-0 -9.33 
-8.64 
GLY335:HN 
 
 
-9.43 
-9.06 
-9.02 
-8.96 
-8.92 
-8.68 
-8.65 
-7.49 
-7.02 
-6.87 
ARG288:HE 
 
 
 
 
 
 
LYS474:HZ2 
LYS474:HZ2 
 
-9.54 
-9.38 
-9.28 
-9.08 
-8.92 
-8.84 
-8.44 
GLN230:HN 
THR256:HG1 
THR256:HG1 
 
 
ASN307:HN 
ASN307:HN 
 
p1.1-0 -6.74 ASN219:HD22 
 
-6.62 
-6.57 
-6.54 
-6.48 
-6.4 
-6.35 
-6.27 
SER342:HN 
GLU343:HN 
 
 
 
ARG288:HE 
 
-7.25 
-7.1 
 
-7.09 
-6.36 
-6.23 
-6.15 
ASN307:HN 
ALA306:HN 
ASN307:HN 
 
THR256:HG1 
 
 
p1.3-0 -8.1 
 
-8.08 
 
-7.76 
 
-7.45 
-7.06 
 
 
 
-6.97 
MET220:HN 
TYR334:HN 
ASN219:HD22 
TYR334:HN 
THR279:HG1 
TYR334:HN 
TYR334:HN 
ALA333:HN 
TYR334:HN 
GLU282:OE1 
THR279:OG1 
ASN219:HD22 
-8.4 
 
-8.18 
 
 
-8.18 
 
 
-7.73 
-7.72 
 
-7.65 
 
GLU343:HN 
GLU291:OE1 
SER342:HN 
GLU343:HN 
GLU291:OE1 
SER342:HN 
GLU343:HN 
 
SER342:HN 
ILE267:HN 
SER342:HN 
ILE267:HN 
SER342:HN 
-7.35 
 
-6.35 
 
 
-6.25 
GLN230:HN 
ASN307:HN 
ASN307:HN 
MET192:HN 
LEU304:O 
THR256:HG1 
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APPENDIX E 
AMINO ACID LIST 
Nonpolar (hydrophobic) amino acids 
Amino acids Three letter code Single letter code 
Glycine Gly G 
Alanine Ala A 
Valine Val V 
Leucine Leu L 
Isoleucine Ile I 
Methionine Met M 
Phenylalanine Phe F 
Tryptophan Trp W 
Proline Pro P 
 
Polar (hydrophilic) amino acids 
Amino acids Three letter code Single letter code 
Serine Ser S 
Threonine Thr T 
Cysteine Cys C 
Tyrosine Tyr Y 
Asparagine Asn N 
Glutamine Gln Q 
 
Electrically charged (negative and hydrophilic) amino acids 
Amino acids Three letter code Single letter code 
Aspartic acid Asp D 
Glutamic acid Glu E 
 
Electrically charged (positive and hydrophilic) amino acids 
Amino acids Three letter code Single letter code 
Lysine Lys K 
Arginine Arg R 
Histidine His/Hsd H 
 
 
